Immunoglobulin G - Articles

Sort by: Newest Most Comments Relevance

Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms by Cheryl Patient Expert

Posted Wed 01 Jul 2009 5:02pm disorder but not full autism (n=27), and age-matched typically developing (TD) controls (n=96). Samples were assayed for systemic levels of immunoglobulin (IgG, IgM, IgA, and IgE... levels. RESULTS: Children with AU have a significantly reduced level of plasma IgG (5.39+/-0.29 mg/mL) compared to the TD (7.72+/-0.28 mg/mL; P <0.001) and DD children (8.23+/-0.49 Read on »

Immunoglobulin-producing Mouse Plasmacytomas by nih.gov Posted Wed 19 Jan 2011 7:00pm binding activities of myeloma proteins To study Ig synthesis To classify the various different classes of Igs (IgG, IgA, IgM) As a fusion partner to make monoclonal antibodies... system in cancer susceptibility. Available for licensing are isolated immunoglobulin-producing mouse plasmacytomas (PCTs). Each tumor produces only one species of monoclonal Read on »

Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. by Leslie M. Healthy Living Professional

Posted Mon 17 Nov 2008 9:19pm Read on »

Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle ce by Jan Posted Sat 27 Mar 2010 12:00am muscle strips revealed a similar effect of SSc IgG that was fully reversible. In contrast to the effect on BeCh, the SSc IgGs caused no significant effect (P > 0.05) on K+ depolarization and 1-adrenoceptor activation by phenylephrine. Western blot studies revealed the specific presence of SSc IgG-M3-R complex. SSc IgGs attenuated M3-R activation, which Read on »

Octagam (Immune Globulin Intravenous (human)) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events by FDA Posted Wed 25 Aug 2010 8:00am [Posted 08/25/2010] AUDIENCE: Risk Manager, Hematology, Pharmacy ISSUE: Octapharma USA Inc. initiated a voluntary market withdrawal of selected lots of Octagam [Immune Globulin Intravenous (human)] 5% Liquid Preparation as a result of an increased number of reported thromboembolic events, some of which were seriou ... Read on »

GammaGard Liquid, Immune Globulin Intravenous (Human) by FDA Posted Fri 04 Jun 2010 1:30pm Audience: Allergy and Immunology, Pediatrics [Posted 06/04/2010] ISSUE: Baxter BioScience and FDA notified healthcare professionals of a market withdrawal being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions associated with two lots of the product ... Read on »

URGENT - Voluntary Market Withdrawal of Octagam [Immune Globulin Intravenous (human)] 5% Liquid Preparation by FDA Posted Tue 24 Aug 2010 12:49pm DATE Market Withdrawal INITIATED: August 20, 2010 PRODUCT / LOT NUMBER/ Expiration date: OCTAGAM [Immune Globulin Intravenous (human)] 5% Liquid Preparation Lot Number Expiration Date Vial Size (gms) A002B8431 1/11/2012 5 A004A8431 1/27/2012 10 A004B8431 ... Read on »

Intravenous Immune Globulin (IVIg) -- Phase 3 Clinical Trial by Bob DeMarco Patient Expert

Posted Fri 26 Mar 2010 10:17am to screening Currently receiving or has received IVIg treatment within five years prior to screening Currently receiving or has received any investigational biologic(s) (e.g. active Read on »

Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease by Bob DeMarco Patient Expert

Posted Fri 02 Oct 2009 10:01pm The Gammaglobulin Alzheimer’s Partnership Study (GAP)has added six new sites to its clinical trial. The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzhei ... Read on »

Evidence against the effectiveness of Oral immunoglobulin in the treatment of Autism. by Nestor L. Doctor of Philosophy

Posted Wed 11 Feb 2009 3:29pm A review of: Benjamin L. Handen, Raun D. Melmed, Robin L. Hansen, Michael G. Aman, David L. Burnham, Jon B. Bruss, Christopher J. McDougle (2009). A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder Journal of Autism and Developmental Disorders DOI Read on »